| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD8b |
| Uniprot No | P10966 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-182aa |
| 氨基酸序列 | MALPVTALLL PLALLLHAAR PSQFRVSPLD RTWNLGETVE LKCQVLLSNP TSGCSWLFQP RGAAASPTFL LYLSQNKPKA AEGLDTQRFS GKRLGDTFVL TLSDFRRENE GYYFCSALSN SIMYFSHFVP VFLPAKPTTT PAPRPPTPAP TIASQPLSLR PEACRPAAGG AVHTRGLDFA CD |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD8b重组蛋白的参考文献示例(注：文献为示例性概括，非真实存在)：
1. **文献名称**：*"High-yield expression and functional characterization of recombinant CD8β in mammalian cells"*
**作者**：Zhang L, et al.
**摘要**：研究报道了在HEK293细胞中重组表达CD8β蛋白的优化策略，通过构建融合标签提高蛋白稳定性，证实其在体外可增强CD8+ T细胞与抗原呈递细胞的结合能力。
2. **文献名称**：*"Crystal structure of the CD8β homodimer and its interaction with MHC class I"*
**作者**：Thompson M, et al.
**摘要**：解析了CD8β同源二聚体的晶体结构，发现其与CD8α异源二聚体的构象差异，并通过突变实验阐明其对MHC I分子结合的亲和力影响。
3. **文献名称**：*"Recombinant CD8β enhances antitumor immunity in a murine melanoma model"*
**作者**：Chen X, et al.
**摘要**：利用重组CD8β蛋白联合免疫疗法，在小鼠黑色素瘤模型中观察到T细胞活性显著提升，肿瘤生长受抑制，表明其作为免疫佐剂的潜力。
4. **文献名称**：*"Prokaryotic expression and purification of soluble CD8β for antibody development"*
**作者**：Kumar S, et al.
**摘要**：开发了基于大肠杆菌的CD8β可溶性表达系统，成功制备高纯度蛋白并用于筛选特异性单克隆抗体，为诊断试剂开发提供基础。
**提示**：实际文献需通过学术数据库(如PubMed、Web of Science)以关键词“CD8β recombinant protein”或“CD8B cloning”检索获取。
CD8b recombinant protein is a genetically engineered form of the CD8β chain, a critical component of the CD8 co-receptor found on the surface of cytotoxic T lymphocytes (CTLs). Native CD8 exists as a heterodimer, typically composed of CD8α and CD8β subunits, which together enhance T-cell receptor (TCR) interactions with major histocompatibility complex class I (MHC-I) molecules presenting antigenic peptides. This interaction is essential for T-cell activation, target cell recognition, and the immune response against infected or cancerous cells. The CD8β chain contributes to stabilizing the CD8αβ heterodimer and fine-tuning TCR signaling, playing a role in thymocyte development and effector T-cell function.
Recombinant CD8b is produced using expression systems such as bacterial, insect, or mammalian cells, enabling scalable and consistent yields for research and therapeutic applications. Its production often involves tagging (e.g., His-tag) to facilitate purification and detection. This engineered protein retains key functional domains, including the extracellular Ig-like domain that binds MHC-I, and is utilized in studies exploring T-cell biology, immune synapse formation, and antigen-specific immune responses. It also serves as a tool in developing immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapies, where CD8β may enhance receptor stability or signaling.
Research applications include investigating CD8β's role in autoimmune diseases, viral infections, and cancer immunotherapy. Its recombinant form allows for controlled experiments to dissect mechanisms of T-cell activation, tolerance, and exhaustion. Additionally, it aids in generating antibodies or inhibitors targeting CD8β for diagnostic or therapeutic purposes. By providing a purified, functional component of the CD8 co-receptor, this recombinant protein supports advancements in understanding adaptive immunity and refining strategies to modulate T-cell-mediated responses.
×
